Evogene, which develops genetically enhanced seeds to elevate crop performance and productivity, announced terms for its IPO on Wednesday. The Rehovot, Israel-based company plans to raise $86 million by offering 5.0 million shares at $17.16 per share. At the midpoint of the proposed range, Evogene would command a market value of $412 million.
Evogene, which was founded in 2000 and booked $18 million in sales for the 12 months ended September 30, 2013, plans to list on the NYSE under the symbol EVGN. Evogene initially filed confidentially on April 26, 2013. Credit Suisse and Deutsche Bank are the joint bookrunners on the deal.
